Literature DB >> 32144695

Federal Spending on Off-Patent Drugs That Lack Generic Competition.

Benjamin N Rome1,2, Aaron S Kesselheim3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32144695      PMCID： PMC7947060          DOI： 10.1007/s11606-020-05752-y

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  3 in total

Review 1.  The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.

Authors:  Aaron S Kesselheim; Jerry Avorn; Ameet Sarpatwari
Journal:  JAMA       Date:  2016 Aug 23-30       Impact factor: 56.272

2.  Prices of Generic Drugs Associated with Numbers of Manufacturers.

Authors:  Chintan V Dave; Abraham Hartzema; Aaron S Kesselheim
Journal:  N Engl J Med       Date:  2017-12-28       Impact factor: 91.245

3.  Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.

Authors:  Ravi Gupta; Thomas J Bollyky; Matthew Cohen; Joseph S Ross; Aaron S Kesselheim
Journal:  BMJ       Date:  2018-03-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.